Yong Yu - Oct 24, 2023 Form 4 Insider Report for GENELUX Corp (GNLX)

Role
VP, Clinical Trial Operations
Signature
/s/ Sean Ryder, Attorney-in-Fact
Stock symbol
GNLX
Transactions as of
Oct 24, 2023
Transactions value $
-$68,151
Form type
4
Date filed
10/25/2023, 04:15 PM
Previous filing
Oct 11, 2023
Next filing
Nov 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GNLX Common Stock Options Exercise $31.2K +5.2K +4.9% $6.00* 111K Oct 24, 2023 Direct
transaction GNLX Common Stock Sale -$99.4K -5.2K -4.67% $19.11 106K Oct 24, 2023 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GNLX Stock Option (right to buy) Options Exercise $0 -5.2K -2.44% $0.00 208K Oct 24, 2023 Common Stock 5.2K $6.00 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 16, 2023.
F2 The weighted average sale price for the transaction reported was $19.106, and the range of prices were between $19.00 and $19.50. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
F3 Immediately exercisable.